The SYNCHRONIZE-1 trial evaluated survodutide in non-diabetic adults with obesity or overweight with at least 1 weight-related complication.
Acceptance of the New Drug Application is based on findings from a phase 2b portion of the open-label REZILIENT1 clinical trial.
Phase 3 ReSPECT trial data show rezafungin is noninferior to standard antimicrobial regimens for the prophylaxis of invasive fungal diseases in HSCT patients.
Coramitug is currently being investigated in the phase 3 CLEOPATTRA trial in approximately 1280 patients with ATTR-CM.
Improvements in some domains of cognitive function seen for patients with cancer receiving chemotherapy reporting cognitive problems.
No significant drug-related differences seen for clinical pain severity, thermal threshold or tolerance, general pain ...
Under the Bridge program, eligible beneficiaries can get Medicare coverage of GLP-1s for obesity for a $50 copay. Extending the short-term GLP-1 Bridge program is good news for eligible Medicare ...
A proprietary extended-release oral minoxidil, VDPHL01, shows superior efficacy and a consistent safety profile vs placebo for hair loss in men.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results